HomeAI · summaries
Storia in 2 fonti
Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma
Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SARC041
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma
Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SARC041
- ·
healio.com
Abemaciclib may be new standard for ‘challenging’ sarcoma subtype
CHICAGO — Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, according to findings presented during ASCO Annual…